文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19相关ARDS的连续长时间俯卧位通气:智利多中心队列研究

Continuous prolonged prone positioning in COVID-19-related ARDS: a multicenter cohort study from Chile.
PubMed 文献 · Ann Intensive Care · 2022-11-28
一句话结论在智利15个ICU的COVID-19中重度ARDS机械通气患者中,全国性实施连续长时间俯卧位(≥48小时直至PaO2:FiO2>200 mmHg)可行,严重不良事件少见,俯卧位时长与死亡率或压疮无关。

该研究为智利15个ICU的回顾性队列,纳入417例COVID-19中重度ARDS机械通气患者,遵循全国性方案实施连续俯卧位≥48小时直至PaO2:FiO2升至200 mmHg以上。首次俯卧位中位时长4(3-5)天,318例(76.3%)仅接受一次俯卧位;主要不良事件为1-2级压疮97例(23.9%),严重不良事件少见,计划外拔管17例(4.2%);90天死亡率36.2%。98例(24%)首次俯卧位>5天者基线ARDS更重,压疮率44%、90天死亡率48%更高,但校正严重程度及混杂因素后,俯卧位时长与死亡率或压疮无关。

要点

  • 全国性连续长时间俯卧位方案可行:15个ICU的417例COVID-19中重度ARDS患者首次俯卧位中位4(3-5)天,318例(76.3%)仅一次俯卧位。
  • 首次俯卧位主要不良事件为1-2级压疮97例(23.9%),严重不良事件少见,计划外拔管17例(4.2%)。
  • 90天死亡率36.2%;首次俯卧位>5天组(98例,24%)基线ARDS更重,压疮率44%、90天死亡率48%更高。
  • 校正严重程度及混杂因素后,俯卧位时长与死亡率或压疮无关,提示长时间俯卧位未对安全性产生不利影响。

适用人群与场景

  • 智利15个重症监护病房的机械通气COVID-19中重度急性呼吸窘迫综合征(ARDS)患者,遵循全国性连续俯卧位方案。
  • 回顾性队列,纳入需要首次俯卧位的患者417例。

诊断标准与关键阈值

  • 连续俯卧位方案:每次俯卧位≥48小时,直至PaO2:FiO2升至200 mmHg以上。
  • 按首次俯卧位时长分层:A组2-3天,B组4-5天,C组>5天。

处置流程与药物剂量

  • 实施连续长时间俯卧位策略,每次俯卧位持续≥48小时并直至PaO2:FiO2>200 mmHg。
  • 记录俯卧位的次数和时长,以及相关生理数据和俯卧位相关不良事件。

红旗征与不能漏的情况

  • 首次俯卧位期间发生1-2级压疮97例(23.9%),严重不良事件少见,计划外拔管17例(4.2%)。

研究设计与关键结果

  • 回顾性队列研究,纳入417例COVID-19中重度ARDS机械通气患者,首次俯卧位中位时长4(3-5)天,318例(76.3%)仅接受一次俯卧位。
  • 首次俯卧位主要不良事件为1-2级压疮97例(23.9%);严重不良事件少见,计划外拔管17例(4.2%)。
  • 90天死亡率36.2%。
  • 98例(24%)为C组(首次俯卧位>5天),基线ARDS更重(PaO2:FiO2更低、通气比更高),压疮率44%、90天死亡率48%更高。
  • 校正严重程度及多个相关混杂因素后,俯卧位时长与死亡率或压疮无关。

证据类型、等级与局限

  • 证据类型:回顾性队列研究,15个重症监护病房参与。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,全国性实施连续长时间俯卧位策略对COVID-19 ARDS患者可行;轻度压疮常见但处于既往描述范围内,严重不良事件少见;俯卧位时长未对安全性产生不利影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Prone positioning is currently applied in time-limited daily sessions up to 24 h which determines that most patients require several sessions. Although longer prone sessions have been reported, there is scarce evidence about the feasibility and safety of such approach. We analyzed feasibility and safety of a continuous prolonged prone positioning strategy implemented nationwide, in a large cohort of COVID-19 patients in Chile.

METHODS: Retrospective cohort study of mechanically ventilated COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS), conducted in 15 Intensive Care Units, which adhered to a national protocol of continuous prone sessions ≥ 48 h and until PaO2:FiO2 increased above 200 mm Hg. The number and extension of prone sessions were registered, along with relevant physiologic data and adverse events related to prone positioning. The cohort was stratified according to the first prone session duration: Group A, 2-3 days; Group B, 4-5 days; and Group C, > 5 days. Multivariable regression analyses were performed to assess whether the duration of prone sessions could impact safety.

RESULTS: We included 417 patients who required a first prone session of 4 (3-5) days, of whom 318 (76.3%) received only one session. During the first prone session the main adverse event was grade 1-2 pressure sores in 97 (23.9%) patients; severe adverse events were infrequent with 17 non-scheduled extubations (4.2%). 90-day mortality was 36.2%. Ninety-eight patients (24%) were classified as group C; they exhibited a more severe ARDS at baseline, as reflected by lower PaO2:FiO2 ratio and higher ventilatory ratio, and had a higher rate of pressure sores (44%) and higher 90-day mortality (48%). However, after adjustment for severity and several relevant confounders, prone session duration was not associated with mortality or pressure sores.

CONCLUSIONS: Nationwide implementation of a continuous prolonged prone positioning strategy for COVID-19 ARDS patients was feasible. Minor pressure sores were frequent but within the ranges previously described, while severe adverse events were infrequent. The duration of prone session did not have an adverse effect on safety.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Cornejo RA, Montoya J, Gajardo AIJ, et al. Continuous prolonged prone positioning in COVID-19-related ARDS: a multicenter cohort study from Chile. Ann Intensive Care. 2022. PMID: 36441352. doi:10.1186/s13613-022-01082-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。